Kailera Therapeutics raised $625 million in a record IPO for an obesity biotech. The company launched in 2024, closed a $400 million Series A, and went public in under a year. Its entire portfolio runs on GLP-1 drugs licensed from China’s Hengrui Pharma, with its entire pipeline built on licensed assets.
The pace is the story. CEO Ron Renaud told FiercePharma he “knew we were in a good spot” before the offering, and he wasn’t wrong: the IPO landed on top of a $400 million private raise that closed just months earlier.
What the public market actually gets is Hengrui’s GLP-1 pipeline in a U.S. wrapper. Hengrui has been licensing westward aggressively; Kailera is the highest-profile beneficiary yet. Kailera’s $625 million signals how far the obesity premium has stretched in two years — and how much appetite remains for China-sourced assets if the U.S. packaging is right.
Two more deals defined the week. Biogen paid $850 million in biobucks to TJ Biopharma for China rights to a late-stage immune antibody. Tortugas Neuroscience emerged with $106 million for four phase 2-stage neuro assets licensed from Hansoh Pharmaceutical and Eisai, including a schizophrenia candidate and a GABA receptor-positive allosteric modulator.
— Diana Kowalski